Author

S.-H. Lee

Observed names: S-H. Lee, S.H. Lee, SungSook Lee

Observed institutions: Samsung Medical Center, Sungkyunkwan University

ORCID: 0009-0007-0522-0781

Observed ORCID: 0009-0007-0522-0781

OpenAlex ID: A5078426092

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

2024 · E. Felip, B.C. Cho, et al. · Annals of Oncology · 114

Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study

2023 · H.A. Jung, S. Park, et al. · ESMO Open · 18

PDF

P1.16-01 Amivantamab and Lazertinib in Treatment-Naive EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

2022 · B.C. Cho, S.-H. Lee, et al. · Journal of Thoracic Oncology · 7

MA07.04 Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC

2022 · M.E. Marmarelis, S.-H. Lee, et al. · Journal of Thoracic Oncology · 6

PDF

MA07.07 Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR-Mutated NSCLC

2025 · B. Besse, P. Tomasini, et al. · Journal of Thoracic Oncology · 4

MA13.06 Amivantamab, Lazertinib Plus Platinum-based Chemotherapy in EGFR-mutated Advanced NSCLC: Updated Results from CHRYSALIS-2

2023 · S.-H. Lee, B.C. Cho, et al. · Journal of Thoracic Oncology · 4

PDF

972O Overall survival for amivantamab plus lazertinib vs osimertinib in Asian participants with first-line EGFR-mutant advanced NSCLC: MARIPOSA subgroup analysis

2025 · H. Hayashi, Y.J. Kim, et al. · Annals of Oncology · 1

EP.12H.02 Amivantamab, An EGFR-MET Bispecific Antibody, with Cetrelimab, An Anti-PD-1 Antibody, In Advanced NSCLC: Phase 1/2 Polydamas

2024 · P.J. Voon, J.-L. Tan, et al. · Journal of Thoracic Oncology · 1

PDF

OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01

2023 · H.A. Yu, Y. Goto, et al. · Journal of Thoracic Oncology · 1

PDF

Heat Exposure and Fall Accidents in Construction: Informing Occupational Safety and Health Policy in Korea

2026 · Duck-Yeon Cho, Eun-Hi Choi, et al. · Safety and Health at Work

1074eP Phase II study of telisotuzumab vedotin-tllv (Teliso-V) monotherapy in patients with previously untreated MET-amplified (METAmp) advanced non-squamous (NSQ) NSCLC

2025 · S-H. Lee, V. Gregorc, et al. · Annals of Oncology

982P Osimertinib (osi) + savolitinib (savo) in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) with MET overexpression and/or amplification (OverExp/Amp) following progressive disease (PD) on osi: SAVANNAH Asian subset

2025 · S-H. Lee, T.M. Kim, et al. · Annals of Oncology

1153P Enhanced pan-cancer early detection: A multi-feature AI model on whole-genome methylation data expands detection to 12 Solid tumors

2025 · S. Jeong, Y. Jeon, et al. · Annals of Oncology

974MO Efficacy of zipalertinib in Asian patients with EGFR exon 20 insertion mutated (Ex20ins) advanced non-small cell lung cancer (NSCLC)

2025 · R.A. Soo, V.H.F. Lee, et al. · Annals of Oncology

Carcinogen exposure patterns and occupational lung cancer in shipyard workers: findings from investigation of work-related disease in South Korea

2025 · SungSook Lee, Eun-Hi Choi, et al. · International Archives of Occupational and Environmental Health

EP.12H.09 Phase 1b/2a Study of ATR Inhibitor Tuvusertib + Anti-PD-1 Cemiplimab in Patients with Advanced Non-Squamous NSCLC

2024 · N. Vokes, L. Paz-Ares, et al. · Journal of Thoracic Oncology

PDF

PP01.31 Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)

2023 · J. Sabari, T.M. Kim, et al. · Journal of Thoracic Oncology

Works count: 17

Citation count: 156

H-index: 4

I10-index: 2